JNNOVA.COM: Keyword Density Checker

Total words: 1573 | 2-word phrases: 421 | 3-word phrases: 443 | 4-word phrases: 454

PAGE INFO

Title	Try to keep the title under 60 characters (6 characters) JNNova
Description	Try to keep the meta description between 50 - 160 characters (0 characters)
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (28 characters) Serving Science & Technology

#	Keyword	Frequency	Density
1	respiratory distress syndrome	3	0.68%
2	jn nova pharma	3	0.68%
3	1 647 622	2	0.45%
4	647 622 2774	2	0.45%
5	the company is	2	0.45%
6	nova pharma inc	2	0.45%
7	and neuroinflammatory indications	2	0.45%
8	cardiopulmonary and neuroinflammatory	2	0.45%
9	in covid19 patients	2	0.45%
10	with potential applications	2	0.45%
11	covid19 with potential	2	0.45%
12	for covid19 with	2	0.45%
13	in cardiopulmonary and	2	0.45%
14	acute respiratory distress	2	0.45%
15	nathan yoganathan phd	2	0.45%
16	622 2774 infojnnovacom	2	0.45%
17	dr nathan yoganathan	2	0.45%
18	yoganathan phd cso	2	0.45%
19	covid19 virus by	1	0.23%
20	countervailing alternative ras	1	0.23%
21	ace2 eliminates the	1	0.23%
22	implicated in the	1	0.23%
23	of ace2 eliminates	1	0.23%
24	targeting of ace2	1	0.23%
25	by targeting of	1	0.23%
26	virus by targeting	1	0.23%
27	this is ascribed	1	0.23%
28	is ascribed to	1	0.23%
29	ii the covid19	1	0.23%
30	alternative ras which	1	0.23%

#	Keyword	Frequency	Density
1	1 647 622 2774	2	0.44%
2	acute respiratory distress syndrome	2	0.44%
3	for covid19 with potential	2	0.44%
4	647 622 2774 infojnnovacom	2	0.44%
5	nathan yoganathan phd cso	2	0.44%
6	dr nathan yoganathan phd	2	0.44%
7	in cardiopulmonary and neuroinflammatory	2	0.44%
8	cardiopulmonary and neuroinflammatory indications	2	0.44%
9	jn nova pharma inc	2	0.44%
10	covid19 with potential applications	2	0.44%
11	has been strongly implicated	1	0.22%
12	reninangiotensin system ras has	1	0.22%
13	patients with ards from	1	0.22%
14	a generalized overproduction of	1	0.22%
15	with ards from other	1	0.22%
16	ards from other causes	1	0.22%
17	from other causes for	1	0.22%
18	other causes for which	1	0.22%
19	to a generalized overproduction	1	0.22%
20	ras has been strongly	1	0.22%
21	ascribed to a generalized	1	0.22%
22	is ascribed to a	1	0.22%
23	this is ascribed to	1	0.22%
24	system ras has been	1	0.22%
25	angiotensin ii the covid19	1	0.22%
26	strongly implicated in the	1	0.22%
27	been strongly implicated in	1	0.22%
28	pathogenesis this is ascribed	1	0.22%
29	the covid19 virus by	1	0.22%
30	ii the covid19 virus	1	0.22%
31	whose loss severely exacerbates	1	0.22%
32	acute symptoms of covid	1	0.22%
33	is responsible for many	1	0.22%
34	ii is responsible for	1	0.22%
35	ang ii is responsible	1	0.22%
36	ards ang ii is	1	0.22%
37	exacerbates ards ang ii	1	0.22%
38	severely exacerbates ards ang	1	0.22%
39	loss severely exacerbates ards	1	0.22%
40	is mediated by angiotensin1–7	1	0.22%

#	URL	Whois	Check
1	https://www.businesswire.com/news/home/20200814005244/en/Canadian-Biotech-JN-Nova-Pharma-Partners-Government	Whois	businesswire.com
2	http://cdn.sci-news.com/images/enlarge7/image_8346e-Antibody-Like-Proteins.jpg	Whois	sci-news.com
3	https://www.youtube.com/watch?v=nfP5N9Yc72A&t=28s	Whois	youtube.com